Grace & White Has Lifted Summit Hotel Pptys Com (INN) Position by $724,100; Clovis Oncology (CLVS) Position Has Increased by Argentiere Capital Ag

August 12, 2018 - By Palma Niemeyer

Clovis Oncology, Inc. (NASDAQ:CLVS) Logo

Argentiere Capital Ag increased its stake in Clovis Oncology Inc (CLVS) by 71.43% based on its latest 2018Q1 regulatory filing with the SEC. Argentiere Capital Ag bought 25,000 shares as the company’s stock declined 12.39% with the market. The hedge fund held 60,000 shares of the health care company at the end of 2018Q1, valued at $3.17M, up from 35,000 at the end of the previous reported quarter. Argentiere Capital Ag who had been investing in Clovis Oncology Inc for a number of months, seems to be bullish on the $1.83B market cap company. The stock increased 0.26% or $0.09 during the last trading session, reaching $34.77. About 659,529 shares traded. Clovis Oncology, Inc. (NASDAQ:CLVS) has declined 11.65% since August 12, 2017 and is downtrending. It has underperformed by 24.22% the S&P500. Some Historical CLVS News: 23/03/2018 – CLOVIS ONCOLOGY BEGINS EARLY ACCESS PROGRAM FOR RUCAPARIB; 03/04/2018 – The European Medicines Agency Accepts Regulatory Submission for LYNPARZA® (olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer; 23/03/2018 – EU MEDICINES AGENCY RECOMMENDS APPROVAL OF CLOVIS ONCOLOGY CLVS.O OVARIAN CANCER DRUG RUBRACA; 02/04/2018 – MYRIAD GENETICS INC – ASTRAZENECA AND MERCK ARE SEEKING APPROVAL OF LYNPARZA IN JAPAN FOR TREATING PATIENTS WITH BRCA-MUTATED METASTATIC BREAST CANCER; 10/04/2018 – CLOVIS – ALLEGED VIOLATIONS RELATE TO CO’S REGULATORY UPDATE IN NOV 2015 THAT FDA REQUESTED MORE CLINICAL DATA ON EFFICACY, SAFETY OF ROCILETINIB; 10/04/2018 – CLOVIS ONCOLOGY – SEC’S ‘WELLS NOTICES’ ALLEGES VIOLATIONS OF SOME PROVISIONS OF SECURITIES ACT OF 1933 AND SECURITIES EXCHANGE ACT OF 1934; 23/03/2018 – Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe; 08/05/2018 – LYNPARZA® (OLAPARIB) TABLETS GET EU APPROVAL FOR TREATMENT OF; 08/05/2018 – Clovis Oncology 1Q Loss $77.7M; 23/03/2018 – CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets

Grace & White Inc increased its stake in Summit Hotel Pptys Inc Com (INN) by 23.01% based on its latest 2018Q1 regulatory filing with the SEC. Grace & White Inc bought 55,700 shares as the company’s stock rose 11.14% while stock markets declined. The institutional investor held 297,749 shares of the consumer services company at the end of 2018Q1, valued at $4.05 million, up from 242,049 at the end of the previous reported quarter. Grace & White Inc who had been investing in Summit Hotel Pptys Inc Com for a number of months, seems to be bullish on the $1.53 billion market cap company. The stock increased 0.48% or $0.07 during the last trading session, reaching $14.58. About 498,057 shares traded. Summit Hotel Properties, Inc. (NYSE:INN) has declined 14.43% since August 12, 2017 and is downtrending. It has underperformed by 27.00% the S&P500. Some Historical INN News: 07/03/2018 – Norges Bank Buys New 1.1% Position in Summit Hotel; 30/04/2018 – Summit Hotel Properties Declares First Quarter 2018 Dividends; 05/04/2018 – SUMMIT HOTEL PROPERTIES – ON MARCH 31, BOARD NAMED JONATHAN CF; 07/03/2018 Agilysys Solutions Selected by The Summit Hotel, Cincinnati to Optimize Efficiency and Enhance the Guest Experience; 02/05/2018 – Summit Hotel 1Q EPS 1c; 05/04/2018 – SUMMIT HOTEL PROPERTIES INC – ON MARCH 31 CFO, GREGORY DOWELL RETIRED FROM CO; 02/05/2018 – Summit Hotel 1Q Rev $140.2M; 20/04/2018 – DJ Summit Hotel Properties Inc, Inst Holders, 1Q 2018 (INN); 02/05/2018 – Summit Hotel 1Q FFO 31c/Shr; 30/03/2018 – Analysis: Positioning to Benefit within Aerojet Rocketdyne, Summit Hotel Properties, Apollo Endosurgery, The KEYW Holding, FARO

Investors sentiment is 1.05 in Q1 2018. Its the same as in 2017Q4. It is without change, as 27 investors sold CLVS shares while 65 reduced holdings. only 27 funds opened positions while 70 raised stakes. 48.28 million shares or 1.64% less from 49.09 million shares in 2017Q4 were reported. Bain Cap Pub Equity Mgmt Ltd Liability Co reported 0.2% stake. Dekabank Deutsche Girozentrale owns 23,750 shares or 0.01% of their US portfolio. Macquarie Group Inc Ltd accumulated 615,870 shares. Laurion Cap Lp reported 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS). Asset Management Inc reported 5,071 shares stake. Ameriprise Finance holds 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS) or 852,951 shares. Hudson Bay Capital Management Ltd Partnership holds 0.07% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 60,000 shares. Plante Moran Financial Ltd Liability Co owns 126 shares. Ny State Common Retirement Fund holds 0% of its portfolio in Clovis Oncology, Inc. (NASDAQ:CLVS) for 48,300 shares. Orbimed Advsrs Lc owns 2.33 million shares. Morgan Stanley owns 405,590 shares or 0.01% of their US portfolio. Pnc Group has 0% invested in Clovis Oncology, Inc. (NASDAQ:CLVS). D E Shaw reported 319,030 shares stake. Fred Alger Management Inc, a New York-based fund reported 121,302 shares. Amundi Pioneer Asset Mgmt has invested 0.02% in Clovis Oncology, Inc. (NASDAQ:CLVS).

More notable recent Clovis Oncology, Inc. (NASDAQ:CLVS) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed’s Antibiotic Faces FDA Panel” on August 09, 2018, also Seekingalpha.com with their article: “Clovis Oncology, Inc. (CLVS) CEO Patrick Mahaffy on Q2 2018 Results – Earnings Call Transcript” published on August 03, 2018, Seekingalpha.com published: “Don’t Give Up On Clovis” on August 08, 2018. More interesting news about Clovis Oncology, Inc. (NASDAQ:CLVS) were released by: Benzinga.com and their article: “66 Biggest Movers From Friday” published on August 06, 2018 as well as Benzinga.com‘s news article titled: “The Daily Biotech Pulse: Ampio Slides On Offering, Sangamo’s Positive Trial Results, Insys Earnings” with publication date: August 09, 2018.

Since February 15, 2018, it had 0 insider purchases, and 4 selling transactions for $978,975 activity. 4,500 shares were sold by SPICKSCHEN THORLEF, worth $270,000.

Argentiere Capital Ag, which manages about $464.87 million and $234.45 million US Long portfolio, decreased its stake in Nxp Semiconductors N V (NASDAQ:NXPI) by 200,000 shares to 140,000 shares, valued at $16.38 million in 2018Q1, according to the filing. It also reduced its holding in Jpmorgan Chase & Co (NYSE:JPM) by 16,220 shares in the quarter, leaving it with 64,080 shares, and cut its stake in Western Digital Corp (NASDAQ:WDC).

Among 20 analysts covering Clovis Oncology (NASDAQ:CLVS), 16 have Buy rating, 0 Sell and 4 Hold. Therefore 80% are positive. Clovis Oncology had 65 analyst reports since September 10, 2015 according to SRatingsIntel. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Buy” rating by Suntrust Robinson on Wednesday, August 24. The company was maintained on Monday, January 25 by Mizuho. WallachBeth Capital maintained the shares of CLVS in report on Monday, May 9 with “Hold” rating. The stock of Clovis Oncology, Inc. (NASDAQ:CLVS) earned “Outperform” rating by Evercore on Thursday, February 22. The firm has “Buy” rating given on Friday, September 23 by Suntrust Robinson. J.P. Morgan maintained it with “Buy” rating and $111.0 target in Wednesday, September 6 report. The firm has “Buy” rating by Stifel Nicolaus given on Monday, January 23. On Sunday, June 10 the stock rating was maintained by RBC Capital Markets with “Buy”. The firm has “Buy” rating by Stifel Nicolaus given on Tuesday, February 27. The firm earned “Neutral” rating on Monday, November 16 by Mizuho.

Grace & White Inc, which manages about $820.58M and $487.21M US Long portfolio, decreased its stake in Dillards Inc Cl A (NYSE:DDS) by 6,150 shares to 31,450 shares, valued at $2.53 million in 2018Q1, according to the filing. It also reduced its holding in Hanover Ins Group Inc Com (NYSE:THG) by 8,549 shares in the quarter, leaving it with 6,675 shares, and cut its stake in Manulife Finl Corp Com (NYSE:MFC).

Among 10 analysts covering Summit Hotel Properties (NYSE:INN), 9 have Buy rating, 0 Sell and 1 Hold. Therefore 90% are positive. Summit Hotel Properties had 36 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Monday, February 26 with “Buy”. Cantor Fitzgerald maintained Summit Hotel Properties, Inc. (NYSE:INN) rating on Thursday, June 29. Cantor Fitzgerald has “Buy” rating and $2000 target. The firm has “Buy” rating by BB&T Capital given on Friday, January 8. The rating was downgraded by Janney Capital to “Neutral” on Monday, November 20. The firm earned “Buy” rating on Thursday, June 22 by RBC Capital Markets. The firm has “Outperform” rating by Raymond James given on Monday, October 30. The rating was upgraded by Bank of America on Friday, March 3 to “Buy”. The firm earned “Buy” rating on Monday, February 26 by RBC Capital Markets. On Monday, August 7 the stock rating was maintained by RBC Capital Markets with “Buy”. Bank of America upgraded the stock to “Buy” rating in Thursday, April 12 report.

More recent Summit Hotel Properties, Inc. (NYSE:INN) news were published by: Globenewswire.com which released: “Analysis: Positioning to Benefit within FIS, Helix Energy, Palatin Technologies, NiSource, Service Corporation …” on August 10, 2018. Also Seekingalpha.com published the news titled: “Summit Hotel Properties, Inc. (INN) CEO Dan Hansen on Q2 2018 Results – Earnings Call Transcript” on August 02, 2018. Bizjournals.com‘s news article titled: “Wall Street short sellers bet against these Austin companies; Parsley Energy, Cirrus Logic have the most” with publication date: August 09, 2018 was also an interesting one.

Investors sentiment increased to 1.26 in Q1 2018. Its up 0.01, from 1.25 in 2017Q4. It increased, as 12 investors sold INN shares while 70 reduced holdings. 26 funds opened positions while 77 raised stakes. 101.70 million shares or 0.37% more from 101.33 million shares in 2017Q4 were reported. Banced Corp accumulated 40,028 shares. Voya Ltd Liability Co accumulated 45,642 shares. Guggenheim Limited Co holds 0.02% or 515,222 shares in its portfolio. Us Bancshares De owns 17,015 shares. Credit Suisse Ag accumulated 0% or 327,260 shares. Aperio Limited Liability Com reported 31,143 shares or 0% of all its holdings. State Of Alaska Department Of Revenue invested in 96,679 shares or 0.03% of the stock. Morgan Stanley invested in 0% or 261,632 shares. 59,309 are held by Royal Bancorporation Of Canada. 1.30 million are owned by Jpmorgan Chase And. Public Sector Pension Investment Board has 66,286 shares for 0.01% of their portfolio. Numerixs Inv reported 0.03% stake. Cubist Systematic Strategies Ltd reported 30,977 shares or 0.02% of all its holdings. Ameritas Inv holds 8,982 shares. Suntrust Banks has 156,850 shares.

Clovis Oncology, Inc. (NASDAQ:CLVS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: